The Trials of ImClone

The Trials of ImClone “A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell.”


The Time Is Right for These Seven Biotechs

The Time Is Right for These Seven Biotechs “In most years, biotechs decline in the spring as investors anticipate a summer hiatus in the conferences where new clinical results are announced. They rally in the fall as the conference schedule and the volume of news increases … Buy when the playing field is biased in […]


Biotech Knockoffs Lure Novartis

Biotech Knockoffs Lure Novartis “A big pharma player is expanding its generics business. Expect others to follow The divide between those making brand-name drugs and those producing generics is about to become a bit less clear. “


Biotech returning to favor

Biotech returning to favor “After a nearly four-year slowdown, money is beginning to flow again into the biotechnology sector. But it’s more a trickle than a torrent. “


Singapore Wants You!

Singapore Wants You! “The future-friendly city-state has an offer bioscientists can’t refuse: unrestricted research, top-notch equipment, and limitless funds. (Just leave your chewing gum at home.)”


Do NOT follow this link or you will be banned from the site!